InterCure Ltd.

NASDAQ:INCR

Drug Manufacturers - Specialty & Generic

Healthcare
$3.98 -3.97%

-$0.04 today

Market cap
$51.63M
Beta
0.57
P/E (TTM)
-4.3
EPS (TTM)
-$0.64
52W Low $0.68High $1.77

Volume 0.01M

Average 0.04M

INCR Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

InterCure Ltd.NASDAQ: INCR

Stock-Based Compensation · Q2 FY2025 · quarter ended Jun 2025

Stock-based compensation grows, but more slowly than its trailing trend

Q2 FY2025 stock-based compensation of ₪442.5K rose 29.0% year over year, behind the +169.6% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -35.2% a year.

Context

  • Stock-based compensation amounted to 0.9% of revenue in FY2025, unchanged from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +29.0% toward the trailing-twelve-month pace of +169.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2025
₪442.5K+0.0% QoQ
Last fiscal yearDec 2025
₪2.43M+6.5% YoY
LTMJun 2025
₪2.48M+169.6% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+29.0%——
1 year+6.5%——
3-year CAGR-35.2%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

ILS · from the cash flow

Latest · FY2025
2.43M ILS
Year-over-year change
+6.5%
4-year CAGR
-21.7%

Stock-Based Compensation vs competitors

How INCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +169.6% is the highest of 9, against a peer median of -35.6%.
  • Stock-based compensation amounts to 1.0% of revenue for INCR, versus a peer median of 7.2%.
INCR Competitors
Stock-Based Compensation for INCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FBIOFortress Biotech, Inc.LTM Mar 2026$22.45M USD-34.1%+7.7%33.9%
AMWLAmerican Well CorporationLTM Mar 2026$16.98M USD-56.1%-31.2%7.2%
CRDLCardiol Therapeutics Inc.LTM Mar 2026CA$11.4M CAD-21.5%+28.8%—
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$4.61M USD+14.2%—117.2%
BMEABiomea Fusion, Inc.LTM Mar 2026$4.16M USD-75.9%-2.7%—
ASRTAssertio Holdings, Inc.LTM Mar 2026$3.08M USD-37.2%-22.8%3.0%
INCRInterCure Ltd.LTM Jun 2025₪2.48M ILS+169.6%-35.2%1.0%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$2.1M USD-12.1%+36.1%—
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$260K CAD-58.7%-47.5%1.4%
Peer median (excluding INCR) —-35.6%-2.7%7.2%

Competitors are the stored peer set for INCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

ILS
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income7.3M43.75M(63.53M)(72.79M)(36.78M)
Depreciation & Amortization7.39M11.7M13.17M15.37M17.15M
Deferred Income Tax11.44M93K2.25M(14.53M)(7.32M)
Stock-Based Compensation6.45M8.91M2.59M2.28M2.43M
Change in Working Capital(1.65M)(3.02M)(43.55M)(9.19M)18.88M
Accounts Receivables8.39M(18.29M)(23.49M)13.26M9.29M
Inventory(17.89M)(75.99M)40.21M(17.44M)15.95M
Accounts Payables2.79M57.03M(47.63M)(8.9M)(8.82M)
Other Working Capital5.06M34.22M(12.63M)3.88M2.46M
Other Non-Cash Items(5.91M)(10.16M)35.44M11.94M22.49M
Operating Cash Flow25.02M51.27M(53.63M)(66.93M)16.84M
Capital Expenditures(14.03M)(19.74M)(2.62M)(4.38M)(3.55M)
Acquisitions (Net)(19.09M)(8.32M)(4.2M)405K1.67M
Purchases of Investments(1.25M)0000
Sales of Investments00000
Other Investing Activities(30.84M)(114.44M)11.59M21.66M(107K)
Investing Cash Flow(65.21M)(142.5M)4.77M17.69M(1.99M)
Debt Repayment65.83M137.73M(61.98M)7.74M(29.13M)
Common Stock Issued128.73M0034M1.5M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.38M(17.28M)(20.91M)(15.29M)(19.03M)
Financing Cash Flow197.94M120.45M(82.89M)26.46M(46.66M)
Effect of Forex Changes(4.54M)7.16M297K(39K)(44K)
Net Change in Cash158.33M36.37M(131.45M)(22.82M)(31.85M)
Free Cash Flow10.99M31.53M(56.25M)(71.3M)13.29M

InterCure Ltd.

NASDAQ:INCR

Intrinsic Alpha fair value

Locked

Current Price

$3.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.